Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency

Aim of this paper is to remind the risk of ototoxicity when using chloroquine and hydroxychloroquine, in particular as prophylactic agents against SARS-CoV-2, during the pandemic. Healthy subjects taking chloroquine and hydroxychloroquine as prophylactic agents against SARS-CoV-2, during the pandemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciorba, Andrea, Skarżyński, Piotr Henryk, Pelucchi, Stefano, Hatzopoulos, Stavros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568171/
https://www.ncbi.nlm.nih.gov/pubmed/33075521
http://dx.doi.org/10.1016/j.jgar.2020.09.030
Descripción
Sumario:Aim of this paper is to remind the risk of ototoxicity when using chloroquine and hydroxychloroquine, in particular as prophylactic agents against SARS-CoV-2, during the pandemic. Healthy subjects taking chloroquine and hydroxychloroquine as prophylactic agents against SARS-CoV-2, during the pandemic, should be screened periodically, at least by Otoacoustic Emissions (OAEs) in order to detect early manifestations of possible cochlear ototoxic damages.

Ejemplares similares